KR101088229B1 - Ｃｂ１ 수용체 조절제로서의 1,5-디페닐-3-피리디닐아미노-1,5-디히드로피롤리딘-2-온 - Google Patents

Ｃｂ１ 수용체 조절제로서의 1,5-디페닐-3-피리디닐아미노-1,5-디히드로피롤리딘-2-온 Download PDF

Info

Publication number
KR101088229B1
KR101088229B1 KR1020097008216A KR20097008216A KR101088229B1 KR 101088229 B1 KR101088229 B1 KR 101088229B1 KR 1020097008216 A KR1020097008216 A KR 1020097008216A KR 20097008216 A KR20097008216 A KR 20097008216A KR 101088229 B1 KR101088229 B1 KR 101088229B1
Authority
KR
South Korea
Prior art keywords
delete delete
phenyl
trifluoromethyl
formula
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097008216A
Other languages
English (en)
Korean (ko)
Other versions
KR20090069316A (ko
Inventor
존 메너트 샤우스
페리 클라크 히스
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20090069316A publication Critical patent/KR20090069316A/ko
Application granted granted Critical
Publication of KR101088229B1 publication Critical patent/KR101088229B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020097008216A 2006-10-23 2007-10-22 Ｃｂ１ 수용체 조절제로서의 1,5-디페닐-3-피리디닐아미노-1,5-디히드로피롤리딘-2-온 Expired - Fee Related KR101088229B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86254006P 2006-10-23 2006-10-23
US60/862,540 2006-10-23
PCT/US2007/082041 WO2008070305A2 (en) 2006-10-23 2007-10-22 1, 5-diphenyl-3-pyridinylamino-1, 5-dihydropyrrolidin-2-one as cbl' receptor modulator

Publications (2)

Publication Number Publication Date
KR20090069316A KR20090069316A (ko) 2009-06-30
KR101088229B1 true KR101088229B1 (ko) 2011-11-30

Family

ID=39386481

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020097008216A Expired - Fee Related KR101088229B1 (ko) 2006-10-23 2007-10-22 Ｃｂ１ 수용체 조절제로서의 1,5-디페닐-3-피리디닐아미노-1,5-디히드로피롤리딘-2-온
KR1020097008214A Expired - Fee Related KR101088236B1 (ko) 2006-10-23 2007-10-22 Ｃｂ1 수용체 조절제로서의 1,5-디페닐-3-벤질아미노-1,5-디히드로피롤리딘-2-온

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097008214A Expired - Fee Related KR101088236B1 (ko) 2006-10-23 2007-10-22 Ｃｂ1 수용체 조절제로서의 1,5-디페닐-3-벤질아미노-1,5-디히드로피롤리딘-2-온

Country Status (23)

Country Link
US (2) US8168659B2 (https=)
EP (2) EP2099784B1 (https=)
JP (2) JP5331002B2 (https=)
KR (2) KR101088229B1 (https=)
CN (2) CN101528733B (https=)
AR (1) AR063497A1 (https=)
AT (1) ATE492543T1 (https=)
AU (1) AU2007329808B2 (https=)
BR (1) BRPI0717347A2 (https=)
CA (2) CA2667372C (https=)
CL (1) CL2007003002A1 (https=)
CY (1) CY1111140T1 (https=)
DE (1) DE602007011495D1 (https=)
DK (2) DK2094684T3 (https=)
EA (2) EA015175B1 (https=)
ES (2) ES2356025T3 (https=)
MX (2) MX2009004053A (https=)
PE (1) PE20080926A1 (https=)
PL (2) PL2094684T3 (https=)
PT (2) PT2099784E (https=)
SI (2) SI2094684T1 (https=)
TW (1) TW200825067A (https=)
WO (2) WO2008070305A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200825067A (en) * 2006-10-23 2008-06-16 Lilly Co Eli CB1 compounds
SI2280961T1 (sl) * 2008-04-22 2012-11-30 Lilly Co Eli Spojine difenil pirolidin ona kot ligandi cb
EA201071222A1 (ru) 2008-04-22 2011-12-30 Эли Лилли Энд Компани Соединения 1,5-дифенилпирролидин-2-она в качестве лигандов cb-1
US20110280813A1 (en) * 2008-11-13 2011-11-17 Alice Prince Neuraminidase inhibitors and uses thereof
EP2593477A2 (en) * 2010-07-15 2013-05-22 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US20240158384A1 (en) * 2020-12-14 2024-05-16 The Board Of Trustees Of The Leland Stanford Junior University Cb2 receptor agonists
WO2023205180A1 (en) 2022-04-19 2023-10-26 Nurix Therapeutics, Inc. Biomarkers for cbl, and compositions and methods for their use
US20230414598A1 (en) 2022-06-22 2023-12-28 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds and antiemetic agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077911A1 (en) 2004-02-17 2005-08-25 Laboratorios Del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20080689T3 (hr) * 2004-02-19 2009-05-31 Solvay Pharmaceuticals B.V. Imidazolinski derivati sa cb1-antagonističkom aktivnosti
US20060035245A1 (en) * 2004-04-20 2006-02-16 Ason Brandon L Modulators of enzymatic nucleic acid elements mobilization
WO2007020502A2 (en) 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Cannabinoid receptor ligands and uses thereof
TW200825067A (en) * 2006-10-23 2008-06-16 Lilly Co Eli CB1 compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077911A1 (en) 2004-02-17 2005-08-25 Laboratorios Del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments

Also Published As

Publication number Publication date
CA2667210A1 (en) 2008-06-12
EA015175B1 (ru) 2011-06-30
PL2094684T3 (pl) 2011-05-31
PE20080926A1 (es) 2008-07-19
ES2356025T3 (es) 2011-04-04
KR101088236B1 (ko) 2011-11-30
US7998985B2 (en) 2011-08-16
US20100016375A1 (en) 2010-01-21
AU2007329807A1 (en) 2008-06-12
EP2094684B1 (en) 2010-12-22
CA2667372A1 (en) 2008-06-12
WO2008070305A3 (en) 2008-08-28
WO2008070306A2 (en) 2008-06-12
MX2009004054A (es) 2009-04-27
EA015745B1 (ru) 2011-10-31
SI2094684T1 (sl) 2011-04-29
BRPI0717347A2 (pt) 2014-01-14
JP5331001B2 (ja) 2013-10-30
MX2009004053A (es) 2009-04-27
EA200970405A1 (ru) 2009-12-30
DK2094684T3 (da) 2011-03-14
CA2667372C (en) 2013-09-03
EP2099784B1 (en) 2012-12-12
EP2094684A2 (en) 2009-09-02
JP2010507589A (ja) 2010-03-11
US20090275618A1 (en) 2009-11-05
ATE492543T1 (de) 2011-01-15
US8168659B2 (en) 2012-05-01
CL2007003002A1 (es) 2008-06-06
PT2094684E (pt) 2011-01-28
KR20090069316A (ko) 2009-06-30
AU2007329808B2 (en) 2013-11-07
PT2099784E (pt) 2013-01-04
CN101528733A (zh) 2009-09-09
WO2008070306A3 (en) 2008-07-31
CY1111140T1 (el) 2015-06-11
EP2099784A2 (en) 2009-09-16
JP5331002B2 (ja) 2013-10-30
CN101528733B (zh) 2013-10-16
DE602007011495D1 (de) 2011-02-03
PL2099784T3 (pl) 2013-05-31
EA200970404A1 (ru) 2009-10-30
DK2099784T3 (da) 2013-01-14
CA2667210C (en) 2013-09-24
ES2398388T3 (es) 2013-03-15
KR20090071613A (ko) 2009-07-01
TW200825067A (en) 2008-06-16
AU2007329808A1 (en) 2008-06-12
SI2099784T1 (sl) 2013-02-28
JP2010507590A (ja) 2010-03-11
AR063497A1 (es) 2009-01-28
WO2008070305A2 (en) 2008-06-12
CN101528732A (zh) 2009-09-09
CN101528732B (zh) 2013-04-03

Similar Documents

Publication Publication Date Title
KR101088229B1 (ko) Ｃｂ１ 수용체 조절제로서의 1,5-디페닐-3-피리디닐아미노-1,5-디히드로피롤리딘-2-온
US7763644B2 (en) Imidazole derivatives, processes for preparing them and their uses
KR100816185B1 (ko) 2-옥소-1-피롤리딘 유도체, 이의 제조 방법 및 용도
JP2007517056A (ja) ピロール及びピラゾールｄａａｏ阻害剤
EA006604B1 (ru) Сочетание агониста (5-ht2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
JP2016504282A (ja) ジヒドロピラゾールｇｐｒ４０モジュレーター
JP5744203B2 (ja) オレキシン受容体拮抗薬としてのプロリンスルフォンアミド誘導体
CA2669996A1 (fr) Derives de pyrrole, leur preparation et leur utilisation en therapeutique
RS60957B1 (sr) Sinergistične kompozicije koje sadrže (r)-dimiracetam (1) i (s)-dimiracetam (2) u ne-racematnom odnosu
AU2007329807B2 (en) 1, 5-diphenyl-3-pyridinylamino-1, 5-dihydropyrrolidin-2-one as CB1 receptor modulator

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20141124

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20141124